Jonge leeftijd voorspelt betere overleving bij stadium II coloncarcinoom, ongeacht chemotherapie

BACKGROUND: This study aimed to evaluate the impact of age on survival outcomes in stage II colon cancer, with a specific focus on comparing patients who received chemotherapy vs. those who did not. METHODS: We conducted a retrospective analysis of data from the SEER database, including patients diagnosed with stage II colon cancer between 2000 and 2020. The study cohort was stratified by chemotherapy treatment status. Kaplan-Meier estimators and multivariate Cox regression models were employed to analyze survival outcomes, with adjustments for sociodemographic, clinicopathological, and treatment-related factors. RESULTS: The study included 24,043 patients diagnosed with stage II colon cancer, among whom 658 were under 40 years of age. Younger patients exhibited a higher prevalence of poorly differentiated/undifferentiated carcinomas and advanced T-stage disease, and were more frequently treated with chemotherapy. Age was identified as a significant predictor of overall survival in both chemotherapy-treated and non-treated groups, with a more pronounced effect observed in the latter. Multivariate analysis demonstrated a progressive increase in mortality risk with advancing age, using the youngest cohort (<40 years) as reference. Subgroup analyses further revealed that younger age significantly influenced overall survival in patients with T3 and T4 tumors, with particularly notable effects in the T3 subgroup. CONCLUSIONS: Younger age is independently associated with improved survival in stage II colon cancer, regardless of chemotherapy administration and despite more advanced disease characteristics at presentation.